Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Amazon Surpasses Walmart in Annual Revenue, Signaling a New Era in Retail Competition 
Meta Platforms Cuts Equity Awards Again Amid Massive AI Investment Push 
HSBC Cuts 10% of U.S. Debt Capital Markets Team Amid Ongoing Business Revamp 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Freedom Finance and Binance Join Forces in Digital Assets 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Citigroup Private Bank Appoints Chad Reddy as West Market Executive in North America 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement awards to Deitmar Berger effective as of May 7, 2018.
The compensation committee of Atara's board of directors granted Dr. Berger a stock option to purchase 85,000 shares of Atara’s common stock, and restricted stock units to acquire 50,000 shares of Atara’s common stock. The stock option and restricted stock units were granted as an inducement material to Dr. Berger entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of $42.05, equal to the per share closing price of Atara's common stock as reported by Nasdaq on May 7, 2018. The awards vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting over the following three years, assuming the employee is continuously employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, allogeneic T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells.
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-410-3012
[email protected]
Steve Klass, Burns McClellan
212-213-0006 x331
[email protected]
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
[email protected]
